1. Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists
- Author
-
Claudia Finamore, Carmen Festa, Bianca Fiorillo, Francesco Saverio Di Leva, Rosalinda Roselli, Silvia Marchianò, Michele Biagioli, Lucio Spinelli, Stefano Fiorucci, Vittorio Limongelli, Angela Zampella, Simona De Marino, Finamore, Claudia, Festa, Carmen, Fiorillo, Bianca, Di Leva, Francesco Saverio, Roselli, Rosalinda, Marchianò, Silvia, Biagioli, Michele, Spinelli, Lucio, Fiorucci, Stefano, Limongelli, Vittorio, Zampella, Angela, and DE MARINO, Simona
- Subjects
pregnane X receptor agonist ,Chemistry (miscellaneous) ,Organic Chemistry ,Drug Discovery ,inflammatory disorder ,1,2,4-oxadiazole ,Molecular Medicine ,Pharmaceutical Science ,Physical and Theoretical Chemistry ,farnesoid X receptor antagonist ,inflammatory disorders ,Analytical Chemistry - Abstract
Compounds featuring a 1,2,4-oxadiazole core have been recently identified as a new chemotype of farnesoid X receptor (FXR) antagonists. With the aim to expand this class of compounds and to understand the building blocks necessary to maintain the antagonistic activity, we describe herein the synthesis, the pharmacological evaluation, and the in vitro pharmacokinetic properties of a novel series of 1,2,4-oxadiazole derivatives decorated on the nitrogen of the piperidine ring with different N-alkyl and N-aryl side chains. In vitro pharmacological evaluation showed compounds 5 and 11 as the first examples of nonsteroidal dual FXR/Pregnane X receptor (PXR) modulators. In HepG2 cells, these compounds modulated PXR- and FXR-regulated genes, resulting in interesting leads in the treatment of inflammatory disorders. Moreover, molecular docking studies supported the experimental results, disclosing the ligand binding mode and allowing rationalization of the activities of compounds 5 and 11.
- Published
- 2023